![Jeffrey Trigilio](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jeffrey Trigilio
Direttore Finanziario/CFO presso
XOMA ROYALTY CORPORATION
Profilo
Jeffrey Trigilio is currently Chief Financial Officer at XOMA Royalty Corp.
Former positions include Chief Executive Officer, CFO & Secretary at Cullinan Mica Corp., Director-Healthcare Investment Banking at RBC Capital Markets LLC from 2017 to 2018, Chief Operating & Financial Officer at Obsidian Therapeutics, Inc., Head-Sales at Bayer AG, Chief Financial Officer at Amylyx Pharmaceuticals, Inc. in 2020, Chief Financial Officer at Cullinan Oncology LLC, Vice President-Corporate Finance at Bluerock Therapeutics, Inc. from 2018 to 2020, and Chief Financial Officer & Treasurer at Cullinan Therapeutics, Inc. from 2020 to 2024.
Education includes an MBA from The Trustees of Columbia University in The City of New York and an undergraduate degree from Cornell University.
Posizioni attive di Jeffrey Trigilio
| Società | Posizione | Inizio |
|---|---|---|
| XOMA ROYALTY CORPORATION | Direttore Finanziario/CFO | 12/01/2026 |
Precedenti posizioni note di Jeffrey Trigilio
| Società | Posizione | Fine |
|---|---|---|
| CULLINAN THERAPEUTICS, INC. | Direttore Finanziario/CFO | 29/03/2024 |
| AMYLYX PHARMACEUTICALS, INC. | Direttore Finanziario/CFO | 01/07/2020 |
Bluerock Therapeutics, Inc.
 Bluerock Therapeutics, Inc. BlueRock Therapeutics is a clinical stage cell therapy company that aims to transform the treatment of degenerative diseases through cell therapy. The company, a wholly-owned subsidiary of Bayer AG, operates as a cornerstone of its Cell & Gene Therapy Platform. BlueRock's mission is to discover and develop cell therapies that can change the way diseases are treated and improve the lives of patients. The team is committed to realizing the potential of regenerative medicine to help patients suffering from disease by developing new and impactful cellular therapies. BlueRock is based in New York. | Corporate Officer/Principal | 01/01/2020 |
RBC Capital Markets LLC
 RBC Capital Markets LLC Investment Banks/BrokersFinance Provides brokerage services | Corporate Officer/Principal | 01/08/2018 |
Obsidian Therapeutics, Inc.
 Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops TIL cell therapies for the treatment of patients with solid tumors | Direttore Finanziario/CFO | - |
Formazione di Jeffrey Trigilio
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
71
Relazioni di 1° grado
11
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 11 |
|---|---|
Bayer AG
 Bayer AG Pharmaceuticals: MajorHealth Technology Provides health care, nutrition and high-tech material services | Health Technology |
XOMA Royalty Corp.
 XOMA Royalty Corp. Pharmaceuticals: MajorHealth Technology Discovers and develops antibody therapeutics | Health Technology |
The Trustees of Columbia University in The City of New York
 The Trustees of Columbia University in The City of New York Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
RBC Capital Markets LLC
RBC Capital Markets LLC Investment Banks/BrokersFinance Provides brokerage services | Finance |
Amylyx Pharmaceuticals, Inc.
 Amylyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceutical products to cure neurodegenerative diseases | Health Technology |
Cullinan Mica Corp.
 Cullinan Mica Corp. Pharmaceuticals: MajorHealth Technology Develops immuno-oncology therapeutics | Health Technology |
Obsidian Therapeutics, Inc.
Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops TIL cell therapies for the treatment of patients with solid tumors | Health Technology |
Cullinan Oncology LLC
 Cullinan Oncology LLC Financial ConglomeratesFinance Provides investment services for cancer treatments | Finance |
Cullinan Oncology, Inc.
 Cullinan Oncology, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
Bluerock Therapeutics, Inc.
Bluerock Therapeutics, Inc. BlueRock Therapeutics is a clinical stage cell therapy company that aims to transform the treatment of degenerative diseases through cell therapy. The company, a wholly-owned subsidiary of Bayer AG, operates as a cornerstone of its Cell & Gene Therapy Platform. BlueRock's mission is to discover and develop cell therapies that can change the way diseases are treated and improve the lives of patients. The team is committed to realizing the potential of regenerative medicine to help patients suffering from disease by developing new and impactful cellular therapies. BlueRock is based in New York. |
